Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504998 · ClinicalTrials.gov registry record · Phase 1
Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
A Phase 1 study of Pancreatic Cancer, sponsored by Epeius Biotechnologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT00504998: Completed Phase 1 study of Pancreatic Cancer, sponsored by Epeius Biotechnologies.
NCT00504998 is a Phase 1 study of Pancreatic Cancer that has completed, run by Epeius Biotechnologies. The registered enrollment target is 20 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00504998, a Phase 1 study of Pancreatic Cancer, has completed, sponsored by Epeius Biotechnologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol.
Conditions Studied
Interventions
- GENETIC Rexin-G
Study Locations (3)
California
- Epeius Clinical Research Unit - San Marino
- Sarcoma Oncology Center - Santa Monica
New York
- Bruckner Oncology - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
What the finished NCT00504998 record still lists
NCT00504998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Rexin-G is the first listed.
NCT00504998 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT00504998 about?
NCT00504998 is a clinical study titled "Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer". The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol.
What is the current status of trial NCT00504998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-07. Estimated completion is 2011-06.
What conditions does trial NCT00504998 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00504998?
The interventions under investigation include: Rexin-G (GENETIC).
Who is sponsoring clinical trial NCT00504998?
This trial is sponsored by Epeius Biotechnologies, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00504998 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00504998's enrollment target sits among peer trials
20 225th of 278 higher than 47 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia